Operates as a cancer treatment company, developing and providing solutions for oncology. Now — the numbers.
This is an established company with proven profits.
Average growth of 34% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $7.7M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 6× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 5 years, sales grew about 34% a year on average.
The stock sits at $0.03. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 4.9 times as much as the market average. Big rallies — and big drops — can both happen fast.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.